All data are based on the daily closing price as of December 5, 2024
s

Shin Nippon Biomedical Laboratories

2395.TSE
10.47 USD
0.19
+1.85%

Overview

Last close
10.47 usd
Market cap
436.03M usd
52 week high
16.53 usd
52 week low
6.87 usd
Target price
9.72 usd

Valuation

P/E
16.7949
Forward P/E
N/A
Price/Sales
2.4173
Price/Book Value
1.8285
Enterprise Value
602.78M usd
EV/Revenue
3.3438
EV/EBITDA
12.5333

Key financials

Revenue TTM
180.27M usd
Gross Profit TTM
86.86M usd
EBITDA TTM
26.82M usd
Earnings per Share
0.62 usd
Dividend
0.2 usd
Total assets
624.27M usd
Net debt
167.49M usd

About

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of vaccines and therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines. Further, the company is involved in the operates geothermal power generation; operates hotel accommodation facilities; and wellbeing businesses, as well as provides cleaning, clerical work, and welfare services. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
  • Symbol
    2395.TSE
  • Exchange
    TSE
  • Isin
    JP3379950003
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Diagnostics & Research
  • CEO
    Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
  • Headquarter
    Kagoshima
  • Web site
    https://www.snbl.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top